⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1231792 | 1.00 | ATAD2 (0.37) | — | |
| SCHEMBL30609151 | 1.00 | — | — | |
| SCHEMBL31403153 | 0.98 | ATAD2 (0.35) | — | |
| Hydrochloric Acid SCHEMBL2199283 | 0.98 | ATAD2 (0.35) | — | |
| SCHEMBL30917957 | 0.98 | ATAD2 (0.35) | — | |
| Water SCHEMBL28196064 | 0.98 | ATAD2 (0.35) | — | |
| SCHEMBL15571194 | 0.90 | ATAD2 (0.31) | — | |
| Phosphoric Acid SCHEMBL17185718 | 0.90 | ADORA2A (0.32) | — | |
| Phosphoric Acid SCHEMBL7587250 | 0.90 | ADORA2A (0.32) | — | |
| Sulfuric Acid SCHEMBL28173989 | 0.90 | ATAD2 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 94925 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144896-A1 | MODIFIED CPG DINUCLEOTIDES FOR RECOMBINANT VIRAL VECTOR PRODUCTION | SIREN BIOTECHNOLOGY, INC. (US) | 2026-05-28 | — | — | US | claimed |
| US-20260146294-A1 | METHODS TO ENRICH NUCLEOTIDE VARIANTS BY NEGATIVE SELECTION | GUARDANT HEALTH, INC. (US) | 2026-05-28 | — | — | US | claimed |
| EP-4747386-A1 | DOUBLE-STRANDED OLIGONUCLEOTIDE AGENTS AND USES THEREOF | Bisirna Therapeutics Pte. Ltd. (SG) | 2026-05-27 | — | — | EP | claimed |
| EP-4748933-A2 | OLIGONUCLEOTIDES FOR INDUCING PATERNAL UBE3A EXPRESSION | F. Hoffmann-La Roche AG (CH) | 2026-05-27 | — | — | EP | claimed |
| EP-4748380-A2 | COMPOSITIONS AND METHODS FOR DECREASING TAU EXPRESSION | Novartis AG (CH) | 2026-05-27 | — | — | EP | claimed |
| EP-4747627-A1 | METHODS AND SYSTEMS FOR PREDICTIVE CLASSIFICATION BY MASS SPECTROMETRY AND TRAINED LARGE SPECTRAL MODELS | Matterworks Inc (US) | 2026-05-27 | — | — | EP | claimed |
| CN-116033908-B | Enhanced oligonucleotides for modulating FUBP1 expression | F. HOFFMANN-LA ROCHE AG (CH) | 2026-05-26 | — | — | CN | claimed |
| CN-122095092-A | Inhibitor for inhibiting inhibin Beta E gene expression and application thereof | — | 2026-05-26 | — | — | CN | claimed |
| CN-122095090-A | Compounds and methods for reducing ATN1 expression | — | 2026-05-26 | — | — | CN | claimed |
| US-12637489-B2 | Silicon containing modified nucleotide analogs | Singular Genomics Systems, Inc. (US) | 2026-05-26 | — | — | US | claimed |
| EP-0371366-A1 | Antiviral agents | SYNTEX (U.S.A.) INC. (US) | 1990-06-06 | — | — | EP | claimed |
| EP-0350004-A2 | Method for determination of pyrogen content | TANABE SEIYAKU CO., LTD. (JP) | 1990-01-10 | — | — | EP | claimed |
| CN-1036578-A | NOVEL FLUOROPHOSPHONATE NUCLEOTIDE DERIVATIVES | MERRELL DOW PHARMA (US) | 1989-10-25 | — | — | CN | claimed |
| EP-0269947-A1 | Antiviral phosphonomethoxyalkylene purine and pyrimidine derivatives | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CS) | 1988-06-08 | — | — | EP | claimed |
| EP-0060565-B1 | FULLY SYNTHETIC CELL CULTURE MEDIUM | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 1986-06-25 | — | — | EP | claimed |
| EP-0133473-A2 | In vivo labelling of polynucleotide sequences | ENZO BIOCHEM, INC. (US) | 1985-02-27 | — | — | EP | claimed |
| US-4381239-A | Method for reducing the pyrogen content of or removing pyrogens from substances contaminated therewith | TANABE SEIYAKU CO., LTD. (JP) | 1983-04-26 | — | — | US | claimed |
| EP-0076647-A2 | Culture media for cells originating from the immune system | HANA Biologics Incorporated (US) | 1983-04-13 | — | — | EP | claimed |
| EP-0060565-A2 | Fully synthetic cell culture medium | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 1982-09-22 | — | — | EP | claimed |
| EP-0015584-A2 | Nucleotides, methods for their preparation and medicaments | Gauri, Kailash Kumar, Dr. Prof. (DE) | 1980-09-17 | — | — | EP | claimed |